| Stratification | ACM... | ACM.HR (95% CI) | MACE... | MACE.HR (95% CI) |
|---|---|---|---|---|
| 06.Obesity:No | | | | |
| Q2 (12 – 14) | | 0.75 (0.72–0.78) **** | | 0.92 (0.90–0.95) ** |
| Q3 (15 – 16) | | 0.66 (0.63–0.70) **** | | 0.88 (0.85–0.91) **** |
| Q4 (> 16) | | 0.62 (0.59–0.65) **** | | 0.84 (0.81–0.87) **** |
| 06.Obesity:Yes | | | | |
| Q2 (12 – 14) | | 0.90 (0.85–0.95) * | | 0.89 (0.86–0.93) ** |
| Q3 (15 – 16) | | 0.71 (0.66–0.75) **** | | 0.84 (0.80–0.88) **** |
| Q4 (> 16) | | 0.71 (0.67–0.75) **** | | 0.87 (0.83–0.91) *** |
| 07.COPD History:No | | | | |
| Q2 (12 – 14) | | 0.78 (0.75–0.81) **** | | 0.91 (0.89–0.93) *** |
| Q3 (15 – 16) | | 0.68 (0.65–0.71) **** | | 0.87 (0.85–0.90) **** |
| Q4 (> 16) | | 0.66 (0.63–0.69) **** | | 0.85 (0.82–0.88) **** |
| 07.COPD History:Yes | | | | |
| Q2 (12 – 14) | | 0.85 (0.80–0.91) ** | | 0.90 (0.84–0.96) |
| Q3 (15 – 16) | | 0.68 (0.63–0.73) **** | | 0.84 (0.77–0.91) ** |
| Q4 (> 16) | | 0.64 (0.60–0.69) **** | | 0.86 (0.80–0.94) * |
| 08.Hypertension History:No | | | | |
| Q2 (12 – 14) | | 0.64 (0.56–0.74) *** | | 0.82 (0.75–0.89) * |
| Q3 (15 – 16) | | 0.58 (0.49–0.68) **** | | 0.81 (0.74–0.90) ** |
| Q4 (> 16) | | 0.53 (0.45–0.62) **** | | 0.75 (0.68–0.83) *** |
| 08.Hypertension History:Yes | | | | |
| Q2 (12 – 14) | | 0.81 (0.79–0.84) **** | | 0.92 (0.90–0.94) *** |
| Q3 (15 – 16) | | 0.69 (0.66–0.71) **** | | 0.87 (0.85–0.90) **** |
| Q4 (> 16) | | 0.66 (0.64–0.69) **** | | 0.86 (0.84–0.89) **** |
| 09.T2DM History:No | | | | |
| Q2 (12 – 14) | | 0.74 (0.71–0.78) **** | | 0.91 (0.89–0.94) ** |
| Q3 (15 – 16) | | 0.62 (0.58–0.65) **** | | 0.87 (0.84–0.90) **** |
| Q4 (> 16) | | 0.63 (0.59–0.66) **** | | 0.86 (0.83–0.90) **** |
| 09.T2DM History:Yes | | | | |
| Q2 (12 – 14) | | 0.87 (0.83–0.91) *** | | 0.91 (0.87–0.94) ** |
| Q3 (15 – 16) | | 0.75 (0.71–0.79) **** | | 0.86 (0.82–0.90) **** |
| Q4 (> 16) | | 0.69 (0.65–0.72) **** | | 0.84 (0.81–0.88) **** |
| 10.MACE History:No | | | | |
| Q2 (12 – 14) | | 0.69 (0.66–0.73) **** | | 0.91 (0.89–0.93) *** |
| Q3 (15 – 16) | | 0.63 (0.59–0.67) **** | | 0.87 (0.84–0.89) **** |
| Q4 (> 16) | | 0.64 (0.61–0.68) **** | | 0.85 (0.83–0.88) **** |
| 10.MACE History:Yes | | | | |
| Q2 (12 – 14) | | 0.88 (0.85–0.92) *** | | |
| Q3 (15 – 16) | | 0.72 (0.68–0.75) **** | | |
| Q4 (> 16) | | 0.67 (0.64–0.71) **** | | |
| 11.Hypersomnia:No | | | | |
| Q2 (12 – 14) | | 0.80 (0.77–0.83) **** | | 0.91 (0.89–0.93) *** |
| Q3 (15 – 16) | | 0.68 (0.65–0.70) **** | | 0.86 (0.84–0.89) **** |
| Q4 (> 16) | | 0.65 (0.63–0.68) **** | | 0.85 (0.82–0.87) **** |
| 11.Hypersomnia:Yes | | | | |
| Q2 (12 – 14) | | 1.14 (0.76–1.71) | | 1.80 (1.30–2.49) |
| Q3 (15 – 16) | | 1.02 (0.66–1.57) | | 1.24 (0.82–1.86) |
| Q4 (> 16) | | 0.65 (0.40–1.04) | | 1.61 (1.11–2.32) |
| 12.Insomina:No | | | | |
| Q2 (12 – 14) | | 0.81 (0.79–0.84) **** | | 0.92 (0.90–0.94) *** |
| Q3 (15 – 16) | | 0.69 (0.66–0.71) **** | | 0.86 (0.84–0.89) **** |
| Q4 (> 16) | | 0.67 (0.64–0.69) **** | | 0.84 (0.82–0.87) **** |
| 12.Insomina:Yes | | | | |
| Q2 (12 – 14) | | 0.69 (0.61–0.79) *** | | 0.86 (0.78–0.95) |
| Q3 (15 – 16) | | 0.54 (0.46–0.63) **** | | 0.97 (0.86–1.10) |
| Q4 (> 16) | | 0.46 (0.39–0.54) **** | | 0.98 (0.87–1.11) |

ACM axis: 0.1  0.5  1  1.2 — HR — Better ← → Worse

MACE axis: 0.1  0.5  1  1.2 — HR — Better ← → Worse